Bandage Soft Contact Lenses for Ocular XXXX .

@entity1 @entity5517 @entity2132
UNASSIGNED: To examine safety and efficacy of bandage soft contact lenses (BSCLs) for ocular chronic @entity2132 ( @entity2132 ), we conducted a phase II clinical trial. Extended-wear BSCLs were applied under daily topical antibiotic prophylaxis. @entity1 completed standardized symptom questionnaires at enrollment and at 2  weeks, 4  weeks, and 3  months afterward. Ophthalmologic assessment was performed at enrollment, at 2  weeks, and afterward as medically needed. Assessments at follow-up were compared with baseline by paired t-test. Nineteen @entity1 with ocular @entity2132 who remained symptomatic despite conventional treatments were studied. The mean Lee eye subscale score was 75.4 at enrollment and improved significantly to 63.2 at 2  weeks (P  =  .01), to 61.8 at 4  weeks (P  =  .005), and to 56.3 at 3  months (P  =  .02). The ocular surface disease index score and 11-point eye symptom ratings also improved significantly. According to the Lee eye subscale, clinically meaningful improvement was observed in 9 @entity1 (47%) at 2  weeks, in 11 @entity1 (58%) at 4  weeks, and in 9 @entity1 (47%) at 3  months. Visual acuity improved significantly at 2  weeks compared with enrollment values. Based on slit lamp exam at 2  weeks, punctate epithelial erosions improved in 58% of the @entity1 , showed stability in 16%, and worsened in 5%. No corneal ulceration or @entity5517 occurred. BSCLs are a widely available, safe, and effective treatment option that improves manifestations of ocular @entity2132 in approximately 50% of @entity1 . This study was registered at www.clinicaltrials.gov as NCT01616056.
